{"name":"Centre for Human Drug Research, Netherlands","slug":"centre-for-human-drug-research-netherlands","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Adalimumab ID","genericName":"Adalimumab ID","slug":"adalimumab-id","indication":"Rheumatoid arthritis","status":"phase_1"},{"name":"Adalimumab SC","genericName":"Adalimumab SC","slug":"adalimumab-sc","indication":"Rheumatoid Arthritis","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Clindamycin 1% topical lotion formulation","genericName":"Clindamycin 1% topical lotion formulation","slug":"clindamycin-1-topical-lotion-formulation","indication":"Other","status":"marketed"},{"name":"Erythromycin 4% topical gel formulation","genericName":"Erythromycin 4% topical gel formulation","slug":"erythromycin-4-topical-gel-formulation","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Adalimumab ID","genericName":"Adalimumab ID","slug":"adalimumab-id","phase":"phase_1","mechanism":"Tumour necrosis factor-alpha inhibitor","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Adalimumab SC","genericName":"Adalimumab SC","slug":"adalimumab-sc","phase":"phase_1","mechanism":"Tumour necrosis factor-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Clindamycin 1% topical lotion formulation","genericName":"Clindamycin 1% topical lotion formulation","slug":"clindamycin-1-topical-lotion-formulation","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erythromycin 4% topical gel formulation","genericName":"Erythromycin 4% topical gel formulation","slug":"erythromycin-4-topical-gel-formulation","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVDZ3S1d0b0NaeE9VTElZb3dUaXVGdGJfV0d5U19pRFpMQlJUV3RZT2VZMzUyLWh2MlZGaVEwY3Y3UXR1OVRieGR6YWlCR1FYNTZ5LUJ1ZEZSMWp1enBYOV96RGVqNWtBdlhHa3Joa2hLTGZfQ3RZVTRXdTlrdzhSRHlWbFc4cVZ0RlBfY3paQUZwSnU1dU1zV3NQdl9pcUR5TmFBdzI1dnhVT0RhT0JwYzhMY0RGWUttTHkxMXp3Wk56aURYUEl1cmppSjM2ckFJQlluY3dyWQ?oc=5","date":"2026-02-12","type":"pipeline","source":"The Association of the British Pharmaceutical Industry | ABPI","summary":"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK - The Association of the British Pharmaceutical Industry | ABPI","headline":"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK - The Associatio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQUnB4c2JucVA2UmNMWjQzU1RXZk9DY3JndXk1Tk9Rb0R6NUVlQkNLbnlQVUUzR3JQNHI4R29IdlFJMHVPUUZUUzNCcTUwSmZ0YVhwcEJySGVUTFI3UnV1U0NPQTlKSnV0MWJZcFRmT2ZadmZ4OFJOZHZuV3R4UHlPa1N1TXJYcWhZaDRmVTZPQ0d3UlgwQlVQM1NXVDZCUlBwbFRMRU9CWjRiZExBYUhTNm5OTFlIWlJ1OWdsR3BpSVRtTlVVWi1vZUEybFJqSGl5bVZTRnlIU09uSXNzZ0E?oc=5","date":"2026-02-03","type":"pipeline","source":"Leids Universitair Medisch Centrum | LUMC","summary":"Faster and more innovative therapies for patients thanks to the unique ecosystem of the Leiden Bio Science Park - Leids Universitair Medisch Centrum | LUMC","headline":"Faster and more innovative therapies for patients thanks to the unique ecosystem of the Leiden Bio Science Park - Leids ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1RMWF2LW1kdkhBUG5EVGIwTkVTVTkyQjNqX29MZzVmeVJwRlA1M21NWUFOT25rbjBfVHFOQkNTdlFvLVJ2QmtqVWJ6ZE5LRVVDbG4xTGVkYlFjZEFIaEctdE12OEVOcGMyMmRJbkZFYmlOWVpWTkVqRTln?oc=5","date":"2026-01-09","type":"trial","source":"Clinical Trials Arena","summary":"NRG doses first participants in Phase I trial for ALS and Parkinson’s - Clinical Trials Arena","headline":"NRG doses first participants in Phase I trial for ALS and Parkinson’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNZGVjME9BRk9LclB1ZjMwcUtWcDJiZkNSd212Z2dUUE9obDFsNmUtVWMxU1JuMkdVZk1TM0tMMWJkdHQ1Vm92NXlVY1dROFBZQUh3dmtUUy02c2RlZl90eWNlT3Q1UjhFd2xsR3BPZVFmUkR0OFZIRDdDQ0p2dHpFX0pUdHQ1dXNNNTN1eg?oc=5","date":"2025-12-03","type":"pipeline","source":"WIRED","summary":"A Fentanyl Vaccine Is About to Get Its First Major Test - WIRED","headline":"A Fentanyl Vaccine Is About to Get Its First Major Test","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNeXZ4RmdEemhrblFjMlEyVFg0dzN3MW4taFhKdzhCcGQ5Y0VLV1hpdVlUTzIzQ19pWmwwNWRJS3AzY0w1M2NBUXkteG9RNG51OS1uYmlZQ19jdzgtX2Q5ZmdIRzRMalVXUkZFZFVIQkd3dnE5blV2eUUwUlYxNk1pTnBhWjc5R0p4dUp4UG56SlZIcThSY1dwalBvLURjOGRBTVNWa0VtUjZwOVBYajFaakotb0F1SU42Y0pydFI4OERnT3BDUmV5alhXVi1SbW9yeW1r?oc=5","date":"2025-07-01","type":"pipeline","source":"Universiteit Leiden","summary":"Luijten appointed as Professor of Human-Relevant Risk Assessment of Chemical Substances - Universiteit Leiden","headline":"Luijten appointed as Professor of Human-Relevant Risk Assessment of Chemical Substances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBjUE9KbU5MdmtRbzZ3djFOUEl0clhIZmlaWWJwSUJHR2xSeGo4akpMcnhvbm84XzByMzBKQTJmQnZJNGE2MXNvaV9oZWxUTHFBblZES195di1adEk3RzQ4?oc=5","date":"2025-04-30","type":"pipeline","source":"Nature","summary":"Mini organs offer alternative method for predicting drug safety and efficacy - Nature","headline":"Mini organs offer alternative method for predicting drug safety and efficacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE15UnI0TkMtRllvczhaeFJNYmtMX2duanJibjVsTjhtbzdmOHNoeVNvY0NETi0wV0JiUUhxRlRKcUJPLTNXMEpkVzZ0YUhUNnhhdkJGTmV0aEJhNWl2TTAtOHhwaWNXLUc0YkE?oc=5","date":"2024-07-16","type":"pipeline","source":"Wiley","summary":"Reflections on Model‐Informed Drug Development - Wiley","headline":"Reflections on Model‐Informed Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQWFRqeTNscGFxR2R5ZVNadmVGMzdqcnhmalBOenc0bGNSOFFDQ1ZWMG1ia013NFhzMDZSUGFKMnZyQTd0TGswb0RMZVFJa1RmWnN0T3ppald5Rk4ydzMxNVF2UFB6bkpfSDAxSjM1c3FRcW8xWXZIM0x3NzFuU3ZXNGdjQlFwZm9KVGM3SnVjdm50UTNDS24wZUo3WkJhVkpubUdFRg?oc=5","date":"2023-11-29","type":"regulatory","source":"novoholdings.dk","summary":"Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation - novoholdings.dk","headline":"Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQNS1tNi1OYUZFUHhGbTE3NEgzbXY1R1JqZDVMSkVfenJxZU5jdWhRTDl6dHRyRnV6YU5DMExiTW9JRm0zUk5PelU3VmNrdjNFNEZHOFJNQ196UEt6NWZDMnNhSDhNUTN4YlJpdW52WHVsc2JKX0RZYzlMX0gtNzRyWGM4MG1GRUU0UE9jSmFJY21MWGs?oc=5","date":"2022-10-11","type":"trial","source":"Labiotech.eu","summary":"Positive results from NMD Pharma myasthenia gravis trial - Labiotech.eu","headline":"Positive results from NMD Pharma myasthenia gravis trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOQzRlRUQxVEd0a18zcjlOaVNWU01CYzZVLVp0bTZJRVB4R3Jjd1Fob3V6bl95RTVIaF8wb1dZbUZDWl9Hc0RpX1owLURzeEFTRVVxeURzRDJBV08tWTlQM0tvaFM2czRSeWFIVTQwb1VlUXkwbHd6Uzc2V1NudTlIbnVEUmIyU2xnbkJfWWt6dTUxZDRwbEl0cjVYVQ?oc=5","date":"2022-09-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Why Algernon is investigating DMT in stroke rehabilitation - drugdiscoverytrends.com","headline":"Why Algernon is investigating DMT in stroke rehabilitation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQd1A5MWF2MjlrMk1uTFE4Z0NWZUJjUnJlY2J3NGhIUjl5dGtpWDhwdW0xTkhSU3V3SHNiYUV1bkJoaVREUE0xV1UxY3dZbDZxS2tUWHlRUnJiVWZLVExUT0dZM1I4eVQ1NlF4OXRDM296cG5HSms5ek9FMElHZXB0Sw?oc=5","date":"2021-11-15","type":"pipeline","source":"Science | AAAS","summary":"Careers Prospects in Clinical Research - Science | AAAS","headline":"Careers Prospects in Clinical Research - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPQXlRbzl4MnJ6Z3JhTmd3bmpuNWhFSkNTMjJmenZQY2gwcFhxSmVBT0ZEODlqbDhJeVJkWEdOdmVrUzVsZFN6S1VjSF9xTV9YMktPVS03TGNHdDBNUmlncDNTMTN6WEIyS19qdDRfazBDYVlGV0RCTzFxUFc0R29pY3ZRWDI5VXBTVDhyc2hB0gGeAUFVX3lxTFBMVGlmZjVJSlR2cFBmaW52eWJyZzd3UndOWHc4aTFzcG5sUE5lMjVGcGd0SjZ5ZVNJdVZKUHA0NUhBeWRxQlg1ekxoWElyNmpCbzdqRVhlR2Z5UjhLZ0VSR0o5NkZ3R0s5Sy0tSEptcUp0ZnRDdTJZSHVSTDljX1ItWE94TGxVVEdNaGhpdlpsVERTaWRSaGNuVDBUalBB?oc=5","date":"2018-11-08","type":"earnings","source":"University of Colorado Anschutz","summary":"A Summer Learning in the Netherlands - University of Colorado Anschutz","headline":"A Summer Learning in the Netherlands","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}